Header

Skip to main content

Seven Rockville companies featured on Washington Business Journal’s largest bioscience employers list

Lab worker writing on test tube

Rockville, the epicenter of the Biotech Corridor is home to a concentration of bioscience companies and research institutions

The Washington Business Journal recently released its 2025 list of the 50 largest bioscience employers in the Washington metropolitan area. Seven companies located in the City of Rockville’s Biotech Corridor were included in the rankings, based on their reported number of metro-area employees.

The Biotech Corridor is home to a concentration of bioscience companies and research institutions concentrated in Rockville. The Corridor’s biotech and life sciences companies feature specializations including clinical research, diagnostics, biopharmaceuticals, and biologics manufacturing. The City of Rockville serves as a hub due to its proximity to federal health agencies, academic institutions, and established industry infrastructure.

The following companies within the City of Rockville are ranked among the region’s largest bioscience employers:

View the list of Washington Business Journal’s 2025 ranking of bioscience employers in the region at bizjournals.com/washington/subscriber-only/2025/08/08/here-are-the-50-largest-bioscience-employers-in-greater.html

BioHealth Capital Region Claims #3 Spot Among Top U.S. Biopharma Clusters in 2025

Aerial photo of NIH Clinical Center building
National Institutes of Health (NIH) Clinical Center - Image credit: National Institutes of Health

The region's third-place ranking is backed by strong performance across metrics including patents, NIH funding, venture capital funding, lab space, and number of jobs

The BioHealth Capital Region, covering Maryland, Virginia, and Washington D.C., ranked as the nation’s third-largest biomedical and pharmaceutical cluster, according to Genetic Engineering & Biotechnology News’ annual list of top U.S. Biopharma regions

Despite challenges like federal funding cuts and workforce reductions at agencies such as the FDA and NIH, the region remains resilient, continuing to attract leading companies and institutions. Its competitiveness reflects decades of scientific excellence. The region’s third-place ranking is backed by strong performance across key biotech metrics. It leads the U.S. in patent production with 79,141 patent families in biotechnology, demonstrating groundbreaking research.

The BioHealth Capital Region ranked third in laboratory space, with 36.8 million square feet of cutting-edge facilities, including the NIH’s 9.2 million square feet in Bethesda. This infrastructure drives innovation and scientific progress. With 4,806 awards worth $3.639 billion in NIH funding, the area ranked third, underscoring confidence in its research capabilities despite budget pressures.

Activity in the Biotech Corridor including AstraZeneca’s $300 million cell therapy manufacturing facility and MilliporeSigma’s $286 million biosafety testing facility have added hundreds of high-paying jobs, cementing the region as a global hub for next-generation therapeutics.

Read the full list of 2025 Top 10 U.S. Biopharma Clusters at www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2025/